Invasive Candidiasis in Critical Care
University Hospital Ostrava
100 participants
Apr 11, 2024
OBSERVATIONAL
Conditions
Summary
The combination of acute phase marker monitoring and the "T2Candida" assay (name of the test) will represent an acceleration of the identification of the causative agent of mycotic infection, a significant improvement in the specificity and positive predictive value of this strategy in the diagnosis of invasive candidiasis and candidemia in ICU patients, thereby improving the clinical condition of patients and reducing the cost of specific antifungal therapy.
Eligibility
Inclusion Criteria6
- critically ill patients
- new onset sepsis
- rise in body temperature >38°C according to The Third Consensus Definitions for Sepsis and Septic Shock
- colonization with Candida spp. from more than 1 non-sterile site
- body temperature >38 °C despite 5 days of broad-spectrum antibiotic therapy with the presence of at least 1 of the following risk factors: abdominal surgery, secondary peritonitis, pancreatitis, central venous catheter (CVC) insertion, total parenteral nutrition (CPV), dialysis, steroid therapy, immunosuppressive therapy, or liver transplantation
- microbiological test results will be reviewed and categorized based on whether Candida sp. is isolated from at least 2 non-sterile sites (±3 days) and whether there is an alternative microbiological diagnosis.
Exclusion Criteria2
- not signing the informed consent with participation in the study
- administration of antifungal therapy prior to collection of the biological material required for the study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The combination of acute phase marker monitoring and the T2Candida assay will be assessed.
Patients will be asked to provide a urine sample for future research (urine biobank).
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06456151